Clinical bottom line
Multisystem inflammatory syndrome in children (MIS-C) is a rare but serious hyperinflammatory condition temporally associated with SARS-CoV-2 infection. While most MIS-C cases require hospitalization, emerging evidence supports the feasibility of outpatient management for selected mild to moderate cases with close monitoring and multidisciplinary follow-up. Current evidence emphasizes early recognition, risk stratification using clinical and biomarker profiles, and tailored immunomodulatory therapy to prevent progression. Outpatient management strategies must include vigilant cardiac and neurological surveillance given the risk of complications. This digest summarizes the current evidence base to inform pediatric clinicians on evidence-based approaches to outpatient MIS-C care, highlighting areas requiring further validation.
What the evidence shows
MIS-C typically presents 2–6 weeks after SARS-CoV-2 exposure with fever, multisystem involvement, and elevated inflammatory markers (Varghese et al., 2022). The syndrome can affect cardiovascular, gastrointestinal, neurological, and hematologic systems, with variable severity (Red Book 2024). Biomarker profiling reveals elevated CRP, ferritin, D-dimer, and cardiac markers such as troponin and BNP, which aid in diagnosis and risk assessment (Indian Journal of Biochemistry and Biophysics, 2020).
Hospitalization remains standard for moderate to severe MIS-C due to risks of shock and cardiac dysfunction. However, recent studies suggest that children with mild symptoms, stable vital signs, and no significant cardiac involvement may be candidates for outpatient management with close follow-up (Migowa et al., 2022). The Kenyan experience demonstrated that resource-limited settings can implement outpatient protocols emphasizing early identification, corticosteroid therapy, and telemedicine monitoring to reduce hospital burden without compromising outcomes.
Neurological manifestations, including headaches and altered mental status, warrant careful outpatient neurological assessment and follow-up, as highlighted in African cohorts (Matovu et al., 2025). Cardiology follow-up is critical; medium-term outpatient cardiology monitoring showed resolution of cardiac abnormalities in most patients but underscored the need for echocardiographic surveillance to detect late sequelae (Jose et al., 2023).
Immunomodulatory treatment typically involves intravenous immunoglobulin (IVIG) and corticosteroids, with outpatient regimens adapting dosing and administration routes to balance efficacy and feasibility (Red Book 2021). Anti-inflammatory therapy initiation in outpatient settings requires protocols for rapid escalation to inpatient care if deterioration occurs.
Caveats and uncertainty
Evidence for outpatient MIS-C management remains limited and largely observational, with few randomized controlled trials. Patient selection criteria for outpatient care are not yet standardized, and risk stratification tools require further validation. Biomarker thresholds predictive of safe outpatient management are not definitively established (Indian Journal of Biochemistry and Biophysics, 2020).
The heterogeneity of MIS-C presentations and the potential for rapid clinical deterioration necessitate cautious outpatient approaches with low thresholds for hospitalization. Neurological and cardiac complications may evolve subclinically, underscoring the importance of multidisciplinary follow-up, which may be challenging in resource-limited or rural settings (Matovu et al., 2025; Migowa et al., 2022).
Long-term outcomes of outpatient-managed MIS-C patients remain underreported, limiting understanding of potential late sequelae. The optimal duration and intensity of outpatient monitoring, including frequency of cardiac imaging and laboratory testing, are not yet defined (Jose et al., 2023).
How this may change practice
Pediatric clinicians should consider outpatient management for carefully selected MIS-C patients with mild disease, stable hemodynamics, and no significant cardiac or neurological involvement, provided that robust follow-up systems are in place. This approach may reduce hospital admissions and resource utilization, especially in settings with limited inpatient capacity.
Implementation of outpatient protocols requires multidisciplinary collaboration, including pediatric infectious disease, cardiology, neurology, and rheumatology input. Use of biomarker panels and clinical scoring systems may assist in risk stratification, though these tools require local validation.
Clinicians should educate families on warning signs warranting urgent reassessment and ensure access to rapid escalation pathways. Telemedicine and community health resources can support outpatient monitoring, particularly in resource-constrained environments.
Ongoing data collection and participation in registries are essential to refine outpatient criteria and optimize long-term outcomes. Until higher-level evidence emerges, outpatient MIS-C management should be considered hypothesis-generating and applied cautiously.